Caliber Imaging & Diagnostics (LCDX) Stock Price

Caliber Imaging & Diagnostics Price

OTC·CLOSED
0.00USD+0.00 (+0.00 %)
Market closed

Over the last 4 years Caliber Imaging & Diagnostics grew revenue by 9.8% annually, reaching 3.34 M USD. For Caliber Imaging & Diagnostics, the net margin of -164.0% is up versus -176.0% a few years ago. The stock trades about 1,500% above its 52-week low.

Caliber Imaging & Diagnostics stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Caliber Imaging & Diagnostics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Caliber Imaging & Diagnostics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Caliber Imaging & Diagnostics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Caliber Imaging & Diagnostics Stock Price History
DateCaliber Imaging & Diagnostics Price
8/12/20260.00 USD
8/10/20260.00 USD
8/7/20260.00 USD
8/6/20260.00 USD
8/5/20260.00 USD
8/4/20260.00 USD
8/3/20260.00 USD
7/31/20260.00 USD
7/30/20260.00 USD
7/29/20260.00 USD
7/28/20260.00 USD
7/27/20260.00 USD
7/23/20260.00 USD
7/22/20260.00 USD
7/21/20260.00 USD
7/20/20260.00 USD
7/17/20260.00 USD
7/16/20260.00 USD
7/15/20260.00 USD
7/14/20260.00 USD
7/13/20260.00 USD
7/10/20260.00 USD
7/9/20260.00 USD
7/8/20260.00 USD
7/7/20260.00 USD
7/6/20260.00 USD
7/2/20260.00 USD
7/1/20260.00 USD
6/30/20260.00 USD
6/29/20260.00 USD
6/26/20260.00 USD
6/25/20260.00 USD
6/24/20260.00 USD
6/23/20260.00 USD
6/22/20260.00 USD
6/18/20260.00 USD
6/17/20260.00 USD
6/16/20260.00 USD
6/15/20260.00 USD
6/12/20260.00 USD
6/11/20260.00 USD
6/10/20260.00 USD
6/9/20260.00 USD
6/8/20260.00 USD
6/5/20260.00 USD
6/4/20260.00 USD
6/3/20260.00 USD
6/2/20260.00 USD
6/1/20260.00 USD
5/29/20260.00 USD
5/28/20260.00 USD
5/27/20260.00 USD
5/26/20260.00 USD
5/22/20260.00 USD
5/21/20260.00 USD
5/20/20260.00 USD
5/19/20260.00 USD
5/18/20260.00 USD
5/15/20260.00 USD
5/14/20260.00 USD
5/13/20260.00 USD
5/12/20260.00 USD
5/11/20260.00 USD
5/8/20260.00 USD
5/7/20260.00 USD
5/6/20260.00 USD
5/5/20260.00 USD
5/4/20260.00 USD
5/1/20260.00 USD
4/30/20260.00 USD
4/29/20260.00 USD
4/28/20260.00 USD
4/27/20260.00 USD
4/24/20260.00 USD
4/23/20260.00 USD
4/22/20260.00 USD
4/21/20260.00 USD
4/20/20260.00 USD
4/17/20260.00 USD
4/16/20260.00 USD
4/15/20260.00 USD
4/14/20260.00 USD
4/13/20260.00 USD
4/10/20260.00 USD
4/9/20260.00 USD
4/8/20260.00 USD
4/7/20260.00 USD
4/6/20260.00 USD
4/2/20260.00 USD
4/1/20260.00 USD
3/31/20260.00 USD
3/30/20260.00 USD
3/27/20260.00 USD
3/26/20260.00 USD
3/25/20260.00 USD
3/24/20260.00 USD
3/23/20260.00 USD
3/20/20260.00 USD
3/19/20260.00 USD
3/18/20260.00 USD
3/17/20260.00 USD
3/16/20260.00 USD
3/13/20260.00 USD
3/12/20260.00 USD
3/11/20260.00 USD
3/10/20260.00 USD
3/9/20260.00 USD
3/6/20260.00 USD
3/5/20260.00 USD
3/4/20260.00 USD
3/3/20260.00 USD
3/2/20260.00 USD
2/27/20260.00 USD
2/26/20260.00 USD
2/25/20260.00 USD
2/24/20260.00 USD
2/23/20260.00 USD
2/20/20260.00 USD
2/19/20260.00 USD
2/18/20260.00 USD
2/17/20260.00 USD
2/13/20260.00 USD
2/12/20260.00 USD
2/11/20260.00 USD
2/10/20260.00 USD
2/9/20260.00 USD
2/6/20260.00 USD
2/5/20260.00 USD
2/4/20260.00 USD
2/3/20260.00 USD
2/2/20260.00 USD
1/30/20260.00 USD
1/29/20260.00 USD
1/28/20260.00 USD
1/27/20260.00 USD
1/26/20260.00 USD
1/23/20260.00 USD
1/22/20260.00 USD
1/21/20260.00 USD
1/20/20260.00 USD
1/16/20260.00 USD
1/15/20260.00 USD
1/14/20260.00 USD
1/13/20260.00 USD
1/12/20260.00 USD
1/9/20260.00 USD
1/8/20260.00 USD
1/7/20260.00 USD
1/6/20260.00 USD
1/5/20260.00 USD
1/2/20260.00 USD
12/31/20250.00 USD
12/30/20250.00 USD
12/29/20250.00 USD
12/26/20250.00 USD
12/24/20250.00 USD
12/23/20250.00 USD
12/22/20250.00 USD
12/19/20250.00 USD
12/18/20250.00 USD
12/17/20250.00 USD
12/16/20250.00 USD
12/15/20250.00 USD
12/12/20250.00 USD
12/11/20250.00 USD
12/10/20250.00 USD
12/9/20250.00 USD
12/8/20250.00 USD
12/5/20250.00 USD
12/4/20250.00 USD
12/3/20250.00 USD
12/2/20250.00 USD
12/1/20250.00 USD
11/28/20250.00 USD
11/26/20250.00 USD
11/25/20250.00 USD
11/24/20250.00 USD
11/21/20250.00 USD
11/20/20250.00 USD
11/19/20250.00 USD
11/18/20250.00 USD
11/17/20250.00 USD
11/14/20250.00 USD
11/13/20250.00 USD
11/12/20250.00 USD
11/11/20250.00 USD
11/10/20250.00 USD
11/7/20250.00 USD
11/6/20250.00 USD
11/5/20250.00 USD
11/4/20250.00 USD
11/3/20250.00 USD
10/31/20250.00 USD
10/30/20250.00 USD
10/29/20250.00 USD
10/28/20250.00 USD
10/27/20250.00 USD
10/24/20250.00 USD
10/23/20250.00 USD
10/22/20250.00 USD
10/21/20250.00 USD
10/20/20250.00 USD
10/17/20250.00 USD
10/16/20250.00 USD
10/15/20250.00 USD
10/14/20250.00 USD
10/13/20250.00 USD
10/10/20250.00 USD
10/9/20250.00 USD
10/8/20250.00 USD
10/7/20250.00 USD
10/6/20250.00 USD
10/3/20250.00 USD
10/2/20250.00 USD
10/1/20250.00 USD
9/30/20250.00 USD
9/29/20250.00 USD
9/26/20250.00 USD
9/25/20250.00 USD
9/24/20250.00 USD
9/23/20250.00 USD
9/22/20250.00 USD
9/19/20250.00 USD
9/18/20250.00 USD
9/17/20250.00 USD
9/16/20250.00 USD
9/15/20250.00 USD
9/12/20250.00 USD
9/11/20250.00 USD
9/10/20250.00 USD
9/9/20250.00 USD
9/8/20250.00 USD
9/5/20250.00 USD
9/4/20250.00 USD
9/3/20250.00 USD
9/2/20250.00 USD
8/29/20250.00 USD
8/28/20250.00 USD
8/27/20250.00 USD
8/26/20250.00 USD
8/25/20250.00 USD
8/22/20250.00 USD
8/21/20250.00 USD
8/20/20250.00 USD
8/19/20250.00 USD
8/18/20250.00 USD
8/15/20250.00 USD
Access this data via the Eulerpool API
Get Free API Key

Caliber Imaging & Diagnostics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2009
2.30 M USD
-3.63 M USD
-4.05 M USD
Jan 1, 2010
2.63 M USD
-3.56 M USD
-4.30 M USD
Jan 1, 2011
3.58 M USD
-6.57 M USD
-15.96 M USD
Jan 1, 2012
2.43 M USD
-9.57 M USD
-9.82 M USD
Jan 1, 2013
3.34 M USD
-4.85 M USD
-5.48 M USD

Caliber Imaging & Diagnostics Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 15, 2026, 4:24 AM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEk USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
20092010201120122013
2.002.003.002.003.00
––50.00-33.3350.00
50.0050.0033.3350.0033.33
1,000.001,000.001,000.001,000.001,000.00
-3.00-3.00-6.00-9.00-4.00
-150.00-150.00-200.00-450.00-133.33
-4.00-4.00-15.00-9.00-5.00
––275.00-40.00-44.44
7.457.452.168.008.38
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Caliber Imaging & Diagnostics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Caliber Imaging & Diagnostics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Caliber Imaging & Diagnostics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Caliber Imaging & Diagnostics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Caliber Imaging & Diagnostics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Caliber Imaging & Diagnostics stock margins

The Caliber Imaging & Diagnostics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Caliber Imaging & Diagnostics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Caliber Imaging & Diagnostics.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2009
53.78 %
-157.65 %
-175.96 %
Jan 1, 2010
56.49 %
-135.36 %
-163.81 %
Jan 1, 2011
47.15 %
-183.63 %
-446.20 %
Jan 1, 2012
1.35 %
-392.94 %
-403.38 %
Jan 1, 2013
19.57 %
-145.23 %
-163.99 %

Caliber Imaging & Diagnostics Stock Revenue, EBIT, Earnings per Share

The Caliber Imaging & Diagnostics earnings per share therefore indicates how much revenue Caliber Imaging & Diagnostics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2009
0.31 USD
-0.49 USD
-0.54 USD
Jan 1, 2010
0.35 USD
-0.48 USD
-0.58 USD
Jan 1, 2011
1.65 USD
-3.04 USD
-7.37 USD
Jan 1, 2012
0.30 USD
-1.20 USD
-1.23 USD
Jan 1, 2013
0.40 USD
-0.58 USD
-0.65 USD

Caliber Imaging & Diagnostics business model & stock analysis

Caliber Imaging & Diagnostics Inc (CID), founded in 2007, is a medical technology company based in Rochester, New York. CID focuses on the development of optical imaging systems used in the diagnosis of tissue and skin diseases. CID was founded by an experienced leadership team who previously worked at Kodak and focused on developing new imaging technologies. The founders of CID recognized a significant unmet need in the diagnosis of skin diseases, as traditional methods such as biopsies are painful and invasive. Therefore, CID developed a revolutionary technology called VivaScope® that provides a non-invasive, painless method of tissue imaging. This technology allows doctors to make rapid decisions about a patient without having to wait for a biopsy. CID aims to distribute its products in the North American market and expand its presence in other regions such as Europe, Asia, and the Middle East. The company aims to benefit from the growing trends in telemedicine and the widespread use of telemedicine tools and wearables. CID has built trusted relationships with many renowned clinics and medical institutes worldwide to test and validate its VivaScope® technology and increase its industry recognition. CID focuses on providing technologies for the diagnosis of skin diseases and tissues. The VivaScope technology is capable of visualizing tissue structures beneath the skin surface at magnifications of up to 1000x. CID offers three main products: VivaScope® System, VivaScope® 1500, and VivaScope® 3000. The VivaScope® system is an advanced diagnostic system approved by the FDA. It uses advanced optics and VegascanTM software to provide TissueMap™ images, allowing doctors to visualize tissue beneath the skin surface. The VivaScope® 1500 is a portable version of the VivaScope® system used for diagnosing superficial skin diseases such as melanomas, basal cell carcinomas, and actinic keratoses. The VivaScope® 3000 is CID's latest product, offering higher resolution and better image quality than the VivaScope® system or the VivaScope® 1500. The VivaScope® system has been developed to enable fast, painless, and non-invasive diagnosis of skin diseases. The technology of the VivaScope® system allows doctors to visualize tissue structures and cellular changes beneath the skin surface, which can help reduce the number of painful skin biopsies. VivaScope® 1500 is a handheld version of the VivaScope® system that is easy to transport and provides doctors with a mobile diagnostic capability. This device is ideal for examining superficial skin diseases such as melanomas, basal cell carcinomas, and actinic keratoses. The VivaScope® 3000 is CID's latest product. This advanced diagnostic system offers higher resolution and better image quality than the VivaScope® system and the VivaScope® 1500. The VivaScope® 3000 features the latest technology and can be used for analyzing skin and tissue. In conclusion, CID is an innovative company specializing in the development of optical imaging systems. The company has developed a revolutionary technology called VivaScope, which helps reduce painful skin biopsies and enables doctors to make quick decisions. With a strong presence in the North American market and growing interest in telemedicine, CID has all the prerequisites to become a key player in a rapidly evolving industry.

Caliber Imaging & Diagnostics SWOT Analysis

Strengths

  • Advanced imaging technology: Caliber Imaging & Diagnostics Inc offers cutting-edge imaging solutions that provide high-resolution and accurate results, giving them a competitive advantage in the market.
  • Advanced imaging technology: Caliber Imaging & Diagnostics Inc offers cutting-edge imaging solutions that provide high-resolution and accurate results, giving them a competitive advantage in the market.
  • Strong intellectual property portfolio: The company holds a significant number of patents and trademarks, which enhances their position in the industry and protects their innovative products.
  • Strong intellectual property portfolio: The company holds a significant number of patents and trademarks, which enhances their position in the industry and protects their innovative products.
  • Established customer base: Caliber Imaging & Diagnostics Inc has successfully built a loyal customer base over the years, including renowned medical institutions, resulting in a steady revenue stream.
  • Established customer base: Caliber Imaging & Diagnostics Inc has successfully built a loyal customer base over the years, including renowned medical institutions, resulting in a steady revenue stream.

Weaknesses

  • Limited market presence: The company currently has a limited market presence and struggles to reach a wider customer base due to intense competition and challenges in expanding its global footprint.
  • Limited market presence: The company currently has a limited market presence and struggles to reach a wider customer base due to intense competition and challenges in expanding its global footprint.
  • High dependence on key customers: Caliber Imaging & Diagnostics Inc heavily relies on a few key customers for a significant portion of its revenue, posing a potential risk if these relationships deteriorate.
  • High dependence on key customers: Caliber Imaging & Diagnostics Inc heavily relies on a few key customers for a significant portion of its revenue, posing a potential risk if these relationships deteriorate.
  • Relatively high production costs: The production process for the company's advanced imaging devices involves expensive technologies and materials, limiting their ability to lower prices and potentially affecting profitability.
  • Relatively high production costs: The production process for the company's advanced imaging devices involves expensive technologies and materials, limiting their ability to lower prices and potentially affecting profitability.

Opportunities

  • Growing demand for non-invasive medical devices: With the increasing preference for non-invasive diagnostic procedures, Caliber Imaging & Diagnostics Inc can capitalize on this trend by developing and marketing innovative, patient-friendly imaging solutions.
  • Growing demand for non-invasive medical devices: With the increasing preference for non-invasive diagnostic procedures, Caliber Imaging & Diagnostics Inc can capitalize on this trend by developing and marketing innovative, patient-friendly imaging solutions.
  • Expansion into emerging markets: The company can explore untapped markets in emerging economies where there is a rising demand for advanced medical technologies and a potential for strategic partnerships.
  • Expansion into emerging markets: The company can explore untapped markets in emerging economies where there is a rising demand for advanced medical technologies and a potential for strategic partnerships.
  • Investment in research and development: By allocating resources to further research and development efforts, Caliber Imaging & Diagnostics Inc can continue to enhance its product portfolio, staying ahead of competitors and catering to evolving customer needs.
  • Investment in research and development: By allocating resources to further research and development efforts, Caliber Imaging & Diagnostics Inc can continue to enhance its product portfolio, staying ahead of competitors and catering to evolving customer needs.

Threats

  • Intense competition: The medical imaging market is highly competitive, with numerous established players and new entrants. Caliber Imaging & Diagnostics Inc must continuously differentiate itself to retain market share and fend off competitive pressures.
  • Intense competition: The medical imaging market is highly competitive, with numerous established players and new entrants. Caliber Imaging & Diagnostics Inc must continuously differentiate itself to retain market share and fend off competitive pressures.
  • Stringent regulatory environment: The company operates in a sector subject to strict regulations and compliance standards. Any failure to meet these requirements can result in substantial financial and reputational damage.
  • Stringent regulatory environment: The company operates in a sector subject to strict regulations and compliance standards. Any failure to meet these requirements can result in substantial financial and reputational damage.
  • Economic uncertainties: Caliber Imaging & Diagnostics Inc is exposed to economic fluctuations, such as recessions or market slowdowns, which could impact customer spending, delay purchasing decisions, and negatively affect the company's financial performance.
  • Economic uncertainties: Caliber Imaging & Diagnostics Inc is exposed to economic fluctuations, such as recessions or market slowdowns, which could impact customer spending, delay purchasing decisions, and negatively affect the company's financial performance.

Caliber Imaging & Diagnostics Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Caliber Imaging & Diagnostics historical P/E ratio, EBIT multiple, and P/S ratio

Caliber Imaging & Diagnostics annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Caliber Imaging & Diagnostics shares outstanding

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2009
7.45 M Stocks
Jan 1, 2010
7.45 M Stocks
Jan 1, 2011
2.16 M Stocks
Jan 1, 2012
8.00 M Stocks
Jan 1, 2013
8.38 M Stocks
Price targets and forecasts for Caliber Imaging & Diagnostics are not yet available.

Caliber Imaging & Diagnostics shareholder structure

% Name
0.14908%
Creand Wealth Management
Creand Wealth Management

Caliber Imaging & Diagnostics Supply Chain

Frequently asked questions about Caliber Imaging & Diagnostics

The business model of Caliber Imaging & Diagnostics Inc revolves around delivering innovative and advanced medical imaging solutions. As a leading provider in the healthcare industry, Caliber Imaging & Diagnostics specializes in developing cutting-edge systems for the diagnosis, treatment, and monitoring of various medical conditions. Their state-of-the-art products and technologies enable high-resolution cellular imaging, offering physicians and researchers comprehensive insights for improved patient care. With a strong commitment to advancing medical imaging capabilities, Caliber Imaging & Diagnostics Inc continues to revolutionize the field of diagnostics, empowering healthcare professionals to make accurate and timely medical decisions.

Caliber Imaging & Diagnostics Inc is primarily active in the healthcare and medical device industries.

The main competitors of Caliber Imaging & Diagnostics Inc in the market are typically companies such as Veracyte, Leica Biosystems, and MetaSystems.

Caliber Imaging & Diagnostics Inc, commonly known as Caliber I.D., is a leading company specializing in cutting-edge imaging and diagnostics solutions. Established in 2007, the company has rapidly grown to become a trusted provider of innovative medical devices and software. Caliber I.D. offers non-invasive, high-resolution imaging tools that aid in the early detection and diagnosis of various diseases, including skin cancer. With a commitment to improving patient care and outcomes, Caliber I.D. continues to develop advanced technologies that assist medical professionals in making accurate diagnoses. The company's dedication to research, development, and innovation has solidified its position as a respected player in the medical imaging industry.

Caliber Imaging & Diagnostics Inc (Caliber ID) has achieved several significant milestones. The company introduced the VivaScope®, a non-invasive imaging technology, which revolutionized the field of cellular imaging and diagnostics. Caliber ID received FDA clearance for the VivaScope® system, enabling its use in diagnosing and monitoring various skin conditions, including non-melanoma skin cancer. The company also launched the VivaScan™, a handheld version of the VivaScope® device, expanding its reach and potential applications. Caliber ID's accomplishments include partnerships with leading healthcare organizations and key opinion leaders, further validating the effectiveness of their technology. Overall, Caliber Imaging & Diagnostics Inc has made remarkable strides in the development and commercialization of innovative diagnostic imaging solutions.

Caliber Imaging & Diagnostics Inc is primarily present in the United States.

Caliber Imaging & Diagnostics Inc represents values of innovation, reliability, and cutting-edge technology. As a company in the medical technology industry, Caliber Imaging & Diagnostics Inc is dedicated to providing advanced imaging and diagnostic solutions for improved patient care. With a focus on precision, accuracy, and efficiency, the company delivers quality products that aid in early detection and diagnosis of diseases. Caliber Imaging & Diagnostics Inc follows a corporate philosophy that prioritizes research, development, and a commitment to delivering the best-in-class medical imaging systems. By combining expertise, sophisticated technologies, and a customer-centric approach, Caliber Imaging & Diagnostics Inc continues to revolutionize the medical imaging landscape.

Converted at the current exchange rate, the Caliber Imaging & Diagnostics share trades at 0.00 EUR (0.00 USD).

Caliber Imaging & Diagnostics Inc. is a rising company in the field of biotechnology, focusing on the development of advanced systems for the diagnosis of common diseases. The company offers innovative product solutions for various industries, including medicine and veterinary. The products are tailored to the customers' needs and are known for their high reliability and accuracy. The business model of Caliber Imaging & Diagnostics includes several divisions specialized in different product categories. The key products currently are the VivaScope, ISO, and SBV-HR. The company works closely with its customers to ensure their requirements are met. Caliber Imaging & Diagnostics aims to take a leading position in the field of medical biotechnology through innovative products, excellent customer service, and collaboration with professionals. The company remains committed to developing and refining its products and services to fully satisfy the needs and demands of its customers. With the VivaScope, ISO, and SBV-HR systems, Caliber Imaging & Diagnostics has developed an excellent portfolio of products that provide reliable information and diagnoses. The company aims to strengthen its market position and continue developing innovative solutions to ultimately contribute to better healthcare.

The revenue cannot currently be calculated for Caliber Imaging & Diagnostics.

The profit cannot currently be calculated for Caliber Imaging & Diagnostics.

The P/E ratio cannot be calculated for Caliber Imaging & Diagnostics at the moment.

The P/S cannot be calculated for Caliber Imaging & Diagnostics currently.

The Eulerpool Quality Score for Caliber Imaging & Diagnostics is 3/10.

The ISIN of Caliber Imaging & Diagnostics is US13001C1053. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Caliber Imaging & Diagnostics is A2QCBX. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Caliber Imaging & Diagnostics is LCDX. The ticker symbol is used to trade Caliber Imaging & Diagnostics shares on the stock exchange.

Caliber Imaging & Diagnostics paid dividends every year for the past 0 years.

Caliber Imaging & Diagnostics is assigned to the 'Health' sector.

The dividends of Caliber Imaging & Diagnostics are distributed in USD.

All fundamentals and in-depth analysis of Caliber Imaging & Diagnostics

Our stock analysis for Caliber Imaging & Diagnostics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Caliber Imaging & Diagnostics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Caliber Imaging & Diagnostics Stock
Caliber Imaging & Diagnostics Revenue→
Caliber Imaging & Diagnostics Stock
Caliber Imaging & Diagnostics Net Income→
Caliber Imaging & Diagnostics Stock
Caliber Imaging & Diagnostics P/E→
Caliber Imaging & Diagnostics Stock
Caliber Imaging & Diagnostics P/S→
Caliber Imaging & Diagnostics Stock
Caliber Imaging & Diagnostics EBIT→
Caliber Imaging & Diagnostics Stock
Caliber Imaging & Diagnostics Dividend→
Caliber Imaging & Diagnostics Stock
Caliber Imaging & Diagnostics Directors Dealings→
Caliber Imaging & Diagnostics Stock
Caliber Imaging & Diagnostics Stocks→
Caliber Imaging & Diagnostics Stock
Caliber Imaging & Diagnostics Market capitalization→
Caliber Imaging & Diagnostics Stock
Caliber Imaging & Diagnostics Debt→
Caliber Imaging & Diagnostics Stock
Caliber Imaging & Diagnostics Liabilities→
Caliber Imaging & Diagnostics Stock
Caliber Imaging & Diagnostics Equity→
Caliber Imaging & Diagnostics Stock
Caliber Imaging & Diagnostics AAQS→
Caliber Imaging & Diagnostics Stock
Caliber Imaging & Diagnostics Employees→
Caliber Imaging & Diagnostics Stock
Caliber Imaging & Diagnostics ROE→
Caliber Imaging & Diagnostics Stock
Caliber Imaging & Diagnostics ROA→
Caliber Imaging & Diagnostics Stock
Caliber Imaging & Diagnostics ROCE→
Caliber Imaging & Diagnostics Stock
Caliber Imaging & Diagnostics News→
Caliber Imaging & Diagnostics Stock
Caliber Imaging & Diagnostics Analyst Price Targets→

Health Stocks

Calidi BiotherapeuticsCalciMedicaCalithera BiosciencesCaina Technology CoCaliway Biopharmaceuticals CoCaduceus Software SystemsCambium BioCadrenal TherapeuticsCambridge Cognition HoldingsCachet Pharmaceutical CoCambridge Nutritional SciencesCabaletta BioAll Stocks A–Z →